![Michael Lyle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Lyle
Technik-/Wissenschafts-/F&E-Leiter bei Welichem Biotech, Inc.
Profil
Michael Lyle is currently the Vice President of Research & Development at Welichem Biotech, Inc. He obtained a doctorate degree from Simon Fraser University.
Aktive Positionen von Michael Lyle
Unternehmen | Position | Beginn |
---|---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2009 |
Ausbildung von Michael Lyle
Simon Fraser University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Welichem Biotech, Inc.
![]() Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | Health Technology |